HRSA redrafts 340B rebate pilot program after courts block the original version

Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns

In his latest set of sweeping tariffs on the pharmaceutical industry, President Donald Trump has announced a 200% levy on imported generic drugs by the year 2029.

BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds

A team of investigators have uncovered a rare genetic mutation that enables some blood cancers to evade both approved Bruton tyrosine kinase inhibitors and newer BTK degraders.

July 31, 2026

Vol.52 No.30

Clinical Roundup

Moffitt-led team develops chemical approach to build safer precision medicines

Researchers at Moffitt Cancer Center have developed a chemical approach that could help make targeted cancer medicines safer and more precise.

July 31, 2026

Vol.52 No.30

In Brief

The V Foundation announces recipients of the 2026 Breaking Barriers in Cancer Research Award

The V Foundation for Cancer Research, a top-rated cancer research charity, announced $11.2 million in funding awarded to 14 scientists through its 2026 Breaking Barriers in Cancer Research Award program.

July 24, 2026

Vol.52 No.29

Clinical Roundup

Vermont researchers discover transmissible cancer in catfish—first ever in a freshwater animal

Mysterious black skin lesions afflicting catfish in Lake Memphremagog and other New England and Canadian lakes are caused by a transmissible cancer—the first ever identified in a freshwater fish species, according to a study led by the University of Vermont and the Vermont Fish and Wildlife Department.

July 24, 2026

Vol.52 No.29

Regulatory News

OMB proposal to sideline peer review sparks widespread opposition
Nearly 500,000 public comments flood in—here are some highlights

The Trump administration’s effort to give political appointees greater authority over federally-funded science is colliding with fierce objections from researchers, universities, medical organizations, and members of Congress.

July 17, 2026

Vol.52 No.28

By Claire Marie Porter

HRSA redrafts 340B rebate pilot program after courts block the original version

YOU MAY BE INTERESTED IN

Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns

BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds

Moffitt-led team develops chemical approach to build safer precision medicines

The V Foundation announces recipients of the 2026 Breaking Barriers in Cancer Research Award

Vermont researchers discover transmissible cancer in catfish—first ever in a freshwater animal

OMB proposal to sideline peer review sparks widespread opposition
Nearly 500,000 public comments flood in—here are some highlights

Renew today!

Subscriber content

Never miss an issue!

Login

HRSA redrafts 340B rebate pilot program after courts block the original version

YOU MAY BE INTERESTED IN

Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns

BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds

Moffitt-led team develops chemical approach to build safer precision medicines

The V Foundation announces recipients of the 2026 Breaking Barriers in Cancer Research Award

Vermont researchers discover transmissible cancer in catfish—first ever in a freshwater animal

OMB proposal to sideline peer review sparks widespread oppositionNearly 500,000 public comments flood in—here are some highlights

Never miss an issue!

Login

Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns

OMB proposal to sideline peer review sparks widespread opposition
Nearly 500,000 public comments flood in—here are some highlights